ORIC NASDAQ
ORIC Pharmaceuticals, Inc.
1W: -7.2%
1M: -7.0%
3M: +11.9%
YTD: +49.5%
1Y: +4.3%
3Y: +89.9%
5Y: -48.6%
$12.21
-0.32 (-2.52%)
Weekly Expected Move ±6.5%
$11
$11
$12
$13
$14
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 13,400 Shares of Company Stock
Engineers Gate Manager LP Purchases New Position in Oric Pharmaceuticals, Inc. $ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC? - simplywall.st
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% Higher - Here's What Happened - MarketBeat
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals (ORIC) Projected to Release Earnings on Tuesday - MarketBeat
ORIC SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC Starts Global Prostate Cancer Trial Expected to Enroll About 600 - Stock Titan
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% - Should You Sell? - MarketBeat
Defilade Capital Management L.P. Purchases Shares of 842,928 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Avoiding Lag: Real-Time Signals in (ORIC) Movement - Stock Traders Daily
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Insider Sale: Director at $ORIC Sells 6,100 Shares - Quiver Quantitative
Oric Pharmaceuticals (ORIC) director trades options, sells 13,100 shares - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews
$ORIC stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Analysts Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $19.27
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - simplywall.st
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan
Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com
Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan
Oric Pharmaceuticals, Inc. SEC Filing (Jul 6, 2026) - Stock Titan
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
$ORIC stock is down 14% today. Here's what we see in our data. | ORIC Stock News - Quiver Quantitative
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Brokerages
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 11.6% – Here’s What Happened
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 136% Potential Upside - DirectorsTalk Interviews
Stock Traders Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC)
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Yahoo Finance
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Analyst Downgrade
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges
12 Health Care Stocks Moving In Wednesday's Intraday Session
What's Behind The Drop In Oric Pharmaceuticals Stock Today?
Biggest stock movers Wednesday: NKE, BYND, TH, PM, and more
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
ORIC Pharma drops after early-stage trial data for prostate cancer therapy
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Oric to advance prostate cancer drug to Phase III trials - Clinical Trials Arena
Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down - Fierce Biotech
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial
12 Health Care Stocks Moving In Tuesday's After-Market Session
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
ORIC Pharmaceuticals stock tumbles 27% after trial update - Investing.com
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Analysts
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained
12 Health Care Stocks Moving In Monday's Intraday Session
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
$ORIC stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
Methanex Posts Downbeat Q4 Results, Joins Gap, Nutex Health, Owlet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade
ORIC Pharmaceuticals GAAP EPS of -$0.30 beats by $0.06
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Short Interest Update
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside
ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript